VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates

分组1 - VistaGen Therapeutics reported a quarterly loss of $0.45 per share, which was better than the Zacks Consensus Estimate of a loss of $0.51, representing an earnings surprise of +10.89% [1] - The company posted revenues of $0.3 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 43.89%, compared to revenues of $0.23 million a year ago [2] - VistaGen shares have declined approximately 13.5% since the beginning of the year, while the S&P 500 has gained 1.4% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.51 on revenues of $0.4 million, and for the current fiscal year, it is -$2.03 on revenues of $0.97 million [7] - The Medical - Biomedical and Genetics industry, to which VistaGen belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]